Having advised multiple major pharmaceutical companies on their manufacturing divestment strategy for more than 40 of their facilities globally, PharmaVentures share their insight to help you successfully divest any surplus sites and therefore optimise your manufacturing operations. Key considerations in this process are safeguarding the quality and continuity of supply, retaining jobs, and assisting the new owners to build and grow profitable new businesses.

It is vital that the correct steps are taken to de-risk the divestment, especially when the seller needs to ensure their future production quality and standards remain high in the hands of third parties and future supply is not interrupted.

Fintan Walton, CEO, Mark Andrews, Managing Director, and Jansen Jacob, Vice President, give their expert insight and experiences on life science M&A to positively transform your next divestment.

This content is restricted to members. To view this content please register or login below to view this content.

Register to receive up-to-date information and advice on tax developments within your industry.